Radioactive drug for advanced neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests a radioactive drug called 211At-MABG for people with advanced neuroendocrine cancers that have stopped responding to other treatments. The drug targets cancer cells that show up on a special MIBG scan, delivering radiation directly to the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of cancer called neuroendocrine cancer that has spread and is not responding to other treatments
- A special scan (MIBG) has shown that your tumor takes up the radioactive tracer
- You are generally well enough to be up and about (ECOG 0-2) and your organs (kidneys, liver, blood counts) are working within safe limits
- You are not pregnant or breastfeeding, and you have not had other cancer treatments within the last 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special radioactive medicine (131I-MIBG) to target and kill cancer cells in people with neuroblastoma or pheochromocytoma that has not responded to other treatments. It may help shrink tumors or slow the disease, and you'll receive a stem cell transplant afterward to help your body recover.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
This trial tests a new radioactive drug, Terbium-161 DOTATATE, for people with advanced neuroendocrine tumors that have stopped responding to a similar treatment called Lu-177 DOTATATE. It aims to see if this new drug is safe and can help shrink tumors.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.